News

NICE commits to speed up access to health tech innovations

UK body aims to get the latest health technology innovations in the hands of professionals and patients faster.

Published

on

NICE has been assisting with the UK's health needs since 1999

UK body, the National Institute for Health and Care Excellence (NICE), has laid out a five year plan to put the latest health technology innovations in the hands of professionals and patients faster.

After reflecting on its experiences with the COVID-19 pandemic, the group has launched a new strategy which will work with companies to accelerate new health innovations.

It is looking to use real-world data to assess these new technologies, using guideline recommendations to help both companies and patients.

NICE is looking to stay ahead of the world’s latest health issues all while incorporating the latest evidence to get involved in the innovation process at an earlier stage.

The body has been producing health guidelines for people in the UK for 22 years, developing quality standards and information services which have benefited those in the healthcare sector.

One example of the group supporting healthcare innovation that Health Tech World recently covered is iRhythm’s Zio XT. The cardiac monitor was given a positive recommendation from NICE for its ability to diagnose a range of heart conditions.

It quickly put this experience to use after the first outbreaks of COVID-19 last year, helping develop guidelines for people in the UK on how to protect themselves from the virus.

Professor Gillian Leng, NICE chief executive, said: “The new strategy sets out a vision for the future where NICE will be more dynamic, work more collaboratively, and continue to build on the excellent foundations of the last 22 years.

“Our work to produce rapid COVID-19 guidelines during the pandemic has hastened our desire for change. We demonstrated that we can be flexible and fleet of foot, without losing the rigour of our work, and we will now look to embed that approach in our day-to-day work.

Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), welcomed the news.

“Today’s strategy sets out a positive vision for the future of NICE; one which will see it evolve with the science that makes these breakthroughs possible.

“Pharmaceutical companies are working on thousands of exciting new medicines and treatments, from rare disease gene therapies to mRNA vaccines for cancer.”

1 Comment

Trending stories

Exit mobile version